Evelo Biosciences Investor Relations Material
Latest events
Q4 2022
Evelo Biosciences
Q3 2023
9 Nov, 2023
Q2 2023
14 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Evelo Biosciences Inc
Access all reports
Evelo Biosciences, Inc. (EVLO) is a clinical-stage biotechnology company engaged in the discovery and development of novel oral medicines. These medicines are designed to act on immune cells within the small intestine, with the aim of achieving systemic effects. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the OTC markets.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
EVLO
Country
🇺🇸 United States